Learn more about the #1 prescribed FDA-approved anti-vascular endothelial growth factor treatment for patients with Wet Age-related Macular Degeneration (Wet AMD).1
EYLEA has been studied in more than 3,000 people with certain diseases of the retina .
EYLEA is a prescription medication given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
EYLEA is an anti– vascular (anti-VEGF) treatment that is given by injection into the eye and works by blocking VEGF. EYLEA blocks VEGF by trapping it between its molecular arms. endothelial growth factor
If you and your eye doctor decide that EYLEA is right for you, we have multiple support options that may be able to help you. Whether you have government insurance (like Medicare), private health insurance, or no coverage for EYLEA, we are here to help.
In 2 clinical studies, 1,815 people with Wet AMD received injections of EYLEA (2 mg) either once every 8 weeks after 3 initial monthly doses or once every 4 weeks or ranibizumab once every 4 weeks.
Both studies measured the percentage of people whose vision was maintained (not losing 15 or more letters, or 3 lines, on the eye-chart ) at 1 year.
Of people treated with EYLEA
in the 2 clinical studies at 1 year,
On average, at one year, people treated with EYLEA in the studieson the eye chart than before treatment.
Results from the clinical studies were seen with an average of 7 to 8 treatments of EYLEA 2 mg dosed every 8 weeks (following 3 initial monthly doses) through 1 year.3
These results are from 2 clinical studies; your individual results may vary. Discuss with your eye care team what treatment schedule with EYLEA may be right for you.
EYLEA is the only FDA-approved treatment for Wet AMD4 with a recommended dose of 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks). Your eye care team will determine the EYLEA dosing schedule that's right for you.
Your eye care team will want to see you regularly to check your vision and also check your treatment progress with EYLEA. Work with your eye care team to make sure you can keep your appointments and stay on your recommended treatment schedule.
EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
As with all therapeutic proteins, there is a potential for an immune response in patients treated with EYLEA.
It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.